Brought to you by:
Merit Medical announces FDA approval of the Wrapsody cell-impermeable endoprosthesis
Merit Medical Systems announced today that the Wrapsody cell-impermeable endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, a press release notes, Merit can begin commercialisation of the device in the USA in…
Vascular Therapies completes enrollment in the ACCESS 2 study
Vascular Therapies has today announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access. Vascular Therapies developed…
VasQ: The next standard-of-care innovation
This advertorial is sponsored by Laminate Medical Technologies. At the 2024 Charing Cross (CX) International Symposium (April 23–25) in London, England, the Vascular Access Masterclass Controversies session delved into the question, “We have new technology, but do we need it?”…
EndoAVF found usually less cost effective compared with sAVF
The Society for Clinical Vascular Surgery (SCVS) 50th Annual Symposium (25–29 March, Miami) hosted a series of abstract presentations. Among them was one by Bianca Mulaney, MD and colleagues including Elizabeth George, MD, Stanford University, Stanford, on the cost effectiveness…
Xeltis presents six-month first-in-human data on aXess graft
Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS; 27–29 April, Porto, Portugal). A press release outlines that six-month data from the FIH trial found…
A call to arms: Reuse of mature venous conduits urged
“Recycle that vein!”—that was the appeal from the authors of a new study that trialled the explantation of mature arteriovenous fistulas (AVFs) from patients with venous outflow obstruction in one extremity and translocation of them to the contralateral extremity. Led…
Shockwave Medical announces US launch of new peripheral IVL catheter
Shockwave Medical announced the full U.S. commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the Food and Drug Administration (FDA). A press release details that the Shockwave L6 catheter is purpose-built to modify calcification in otherwise difficult-to-treat…
Amplifi vein dilation system continues to show promise following latest first-in-human study update
An update from the first-in-human study assessing the Amplifi vein dilation system (Artio Medical) was delivered by Surendra Shenoy, MD, from Washington University School of Medicine in St Louis, during the first-ever late-breaking clinical trials session at this year’s Venous Endovascular…
MVSS 2022: Research on hemodialysis access surgery attracts inaugural Midwestern Vascular disparities award
The authors behind a new study that found “significant differences” in hemodialysis vascular access outcomes after first-time arteriovenous (AV) fistula or graft creation “directly related” to a patient’s race said the findings speak “to an injustice within the field of vascular surgery.” The research…
Gore acquires InnAVasc Medical
Gore has announced the acquisition of InnAVasc Medical, a privately held medical technology company focused on advancing care for patients with end-stage renal disease who utilise graft circuits for dialysis treatment. Jeffrey Lawson, MD, PhD, and Shawn Gage, PA-C, of…